All posts

Haywood launches coverage of TECSYS with a buy rating

Tecsys CEO Peter Brereton.

Strong quarterly results, quality management and record bookings are just some of the reasons why Haywood Securities’ Pardeep Sangha likes TECSYS Inc. (TECSYS Stock Quote, Chart TSX:TCS).

The analyst launched coverage of the stock on Thursday, rating it a “Buy” with a $19.00 target price, representing a 43.5 per cent return on investment as of publication date.

Montreal-based TECYSYS, which provides supply chain management software for the healthcare industry as well as industries with complex distribution networks, has seen its share price drop 21 per cent year-to-date, which Sangha attributes to the overall market selloff. The company has also faced a climate of uncertainty surrounding healthcare policy in the US, which has hampered its growth, says Sangha, but the company should see revenue grow by ten per cent over its fiscal 2019 (ending April 31, 2019) and by 18 per cent in fiscal 2020, he adds.

“Revenue growth is driven by increased healthcare spending, contribution from the OrderDynamics acquisition, expansion into hospital pharmacies and a strong pipeline from existing and new customers,” the analyst says.

The analyst points out that TCS grew its backlog to $51.7 million by the end of its Q2 (ended October 31), which compares to last year’s $42.2 million, and had signed six new accounts over the quarter, bringing its bookings to $16.2 million, notably increasing its bookings from the company’s existing healthcare customer base by 196 per cent year-over-year.

“We like TECSYS because of its experienced management team, solid track record, strong balance sheet, large market opportunity, return to growth, and renewed focus on acquisitions,” says Sangha.

The analyst expects revenue of $77.9 million in FY19 with EBITDA of $6.8 million and revenue of $92.0M in FY20 with EBITDA of $11.6 million.

Tagged with: tcs
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you sell your Costco stock?

Roth Capital Markets analyst Bill Kirk lowered his expectations for Costco Wholesale (Costco Stock Quote, Chart, News, Analysts, Financials NASDAQ:COST)… [Read More]

1 day ago

This analyst just raised his price target on TeraWulf

Roth Capital Markets analyst Darren Aftahi raised his target price on TeraWulf (TeraWulf Stock Quote, Chart, News, Analysts, Financials NASDAQ:WULF)… [Read More]

1 day ago

Standard Lithium wins price target raise at Roth

Roth Capital Markets analyst Joe Reagor raised his price target for Standard Lithium (Standard Lithium Stock Quote, Chart, News, Analysts,… [Read More]

2 days ago

Should you sell your Air Canada stock?

National Bank Financial Capital Markets analyst Cameron Doerksen has downgraded Air Canada (Air Canada Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 days ago

Should you sell your Motorola stock?

Caldwell Investment Management president and CEO Brendan Caldwell told BNN Bloomberg’s Market Watch on Sept. 22 that Motorola Solutions (Motorola… [Read More]

3 days ago

Canada is entering “peak aging”, economist warns

RBC assistant chief economist Cynthia Leach warned in a Sept. 24 report that Canada is entering “peak aging” as the… [Read More]

3 days ago